BMS Seeks FDA Priority Review for Krazati in Advanced Colorectal Cancer
Bristol Myers Squibb (BMS; NYSE: BMY) has submitted a priority review application to the U.S....
Combination therapy
Immune-Onc Therapeutics Partners with Roche for Phase Ib/II Study of IO-108 in Liver Cancer
Immune-Onc Therapeutics Inc., based in the U.S., is entering into a collaboration with Roche (SWX:...
Innovent Biologics Partners with ImmVirX to Launch Clinical Study Combining Tyvyt and IVX037
Innovent Biologics Inc. (HKG: 1801), based in China, has announced the signing of a clinical...
Jacobio Pharma Gets CDE Green Light for Phase III Study Combining Gleevec Inhibitors in NSCLC
Jacobio Pharma (HKG: 1167), a China-based pharmaceutical company, has announced that it has received approval...
Laekna Therapeutics Reports Phase II Data for Afuresertib in Platinum-Resistant Ovarian Cancer
Laekna Therapeutics Shanghai Co., Ltd, a China-based pharmaceutical company, has announced topline data from the...
BMS’s Opdivo-Yervoy Combo Cuts Cancer Progression Risk by 79% in Phase III Study
Bristol Myers Squibb (BMS; NYSE: BMY) has published late-stage and long-term data for its anti-PD-1...
AstraZeneca’s Imfinzi Meets Primary Endpoint in Hepatocellular Carcinoma Trial
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced the successful completion of the primary endpoint...
Beijing Aosaikang Initiates Phase III Trial for Advanced Gastric Cancer Treatment
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has registered a Phase...
Eisai and Medivir’s Combo Therapy Advances in Liver Cancer with Positive Trial Results
Japanese pharmaceutical company Eisai’s (TYO: 4523) kinase inhibitor Lenvima (Lenvatinib), combined with Swedish partner Medivir’s...
RemeGen’s MSLN-Targeted ADC RC88 Clears to Begin Phase I/IIa Study in China
RemeGen Co., Ltd (HKG: 9995; SHA: 688331), a leading Chinese biotech firm, has announced that...
Bio-Thera Solutions Receives NMPA Approval for Combined Phase Ib/II Study of BAT7104 and BAT4706
Bio-Thera Solutions Ltd (SHA: 688177), a Chinese biopharmaceutical company, has announced that it has received...
Hengrui Pharmaceuticals Gets NMPA Green Light for Phase Ib/II Study of SHR-A1921 Combo in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...
Jiangsu Hengrui Pharmaceuticals Advances Novel Cancer Therapies with NMPA Clinical Trial Approval
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...
Innovent Biologics Partners with Xuanzhu Biopharma for Clinical Trial of Sintilimab and KM-501 in Advanced Tumors
Innovent Biologics, Inc. (HKG: 1801), based in China, has entered into a clinical trial collaboration...
Konruns Pharmaceutical Receives NMPA Go-Ahead for KC1036 Esophageal Cancer Study
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has received approval from the National Medical Products...
J&J’s Rybrevant-Lazertinib Combo Accepted for FDA Review in NSCLC
The US Food and Drug Administration (FDA) has accepted for review Johnson & Johnson’s (J&J;...
FDA Approves Pfizer-Astellas-MSD Combo Therapy for Advanced Urothelial Cancer
Pfizer (NYSE: PFE), Astellas (TYO: 4503), and Merck, Sharp & Dohme (MSD; NYSE: MRK) have...
Bio-Thera Solutions Gets NMPA Green Light for PD-1 Inhibitor BAT1308 in Endometrial Cancer
Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...
BMS Presents Promising Golcadomide Trial Results for Non-Hodgkin Lymphomas
Bristol Myers Squibb (BMS; NYSE: BMY) has presented results from Phase I and Phase I/II...
HutchMed’s Elunate-Tyvyt Combination Study for Renal Cell Carcinoma Completes Enrollment
China-based HutchMed (NASDAQ: HCM) has announced the completion of patient enrollment in its Phase II/III...